Spots Global Cancer Trial Database for Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Official Title: A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.
Study ID: NCT00430846
Interventions
Study Description
Brief Summary: Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Washington University, St. Louis, Missouri, United States
Weill Cornell Medical College, New York, New York, United States
University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Andres Forero, MD
Affiliation: University of Alabama at Birmingham
Role: PRINCIPAL_INVESTIGATOR
Name: Anas Younes, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Nancy Bartlett, MD
Affiliation: Washington University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: John Leonard, MD
Affiliation: Weill Medical College of Cornell University
Role: PRINCIPAL_INVESTIGATOR
Name: Dana Kennedy, PharmD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
